Eye Serum & Patch: Lightweight Delivery, Film Former & Hydrogel Patch Specification

Overview #

The eye contour is not just delicate skin. It’s a formulation constraint. Thin stratum corneum, constant movement, lymphatic pooling, and zero tolerance for irritation — these factors together mean that what works in a face serum brief will fail here. When brand partners come to us with an eye serum or patch concept, the first thing we ask is not “what actives do you want?” It’s “what delivery format are you actually committing to?” Because the format decision locks in almost every other parameter downstream — viscosity ceiling, preservative system, film former selection, patch substrate, and packaging. Get that wrong early and you’re rebuilding the formula at week 10.

The Four Delivery Formats We Actually Work With #

Eye serums and patches are not one category. In our lab, we treat them as four distinct format families, each with its own rheology target, active loading ceiling, and failure mode.

Lightweight aqueous serum is the workhorse. Target viscosity: 500–3,000 mPa·s at 25°C. This range gives the slip and spreadability the eye area needs without dragging. Go above 4,000 mPa·s and applicators start pulling at the orbital bone. We’ve seen that cause consumer complaints even when the formula itself is fine.

Film-forming serum is where things get interesting — and where most briefs underestimate the complexity. The film former has to deposit a continuous, flexible layer that moves with the skin through 10,000+ blinks per day without flaking or pilling. That’s a mechanical spec, not just a cosmetic one.

Hydrogel patch is a separate manufacturing track entirely. We’re casting a cross-linked polymer matrix, loading actives into it, and then die-cutting to shape. The gel must hold together during handling but release actives at a controlled rate once in contact with skin temperature and moisture.

Microencapsulated serum sits across all three formats as an add-on layer. Encapsulation sounds great until you price it — roughly 3× the raw material cost for the encapsulated fraction, and that’s before you factor in the compatibility testing with your base system.

Critical Selection Criterion 1: Film Former Chemistry and the Flexibility Threshold #

This is usually where projects go sideways. A film former that performs beautifully on a forearm panel will crack and pill around the orbital bone within 20 minutes of application. The reason is simple: the eye area undergoes more mechanical deformation per unit area than almost any other facial zone.

Our threshold for film former selection is an elongation-at-break value of ≥150% when tested as a free-standing film at 23°C, 50% RH. Below that number, we’ve consistently seen flaking complaints in consumer wear tests. The chemistry options we work with most are polyvinyl alcohol (PVA) at 1–3%, acrylates/C10-30 alkyl acrylate crosspolymer at 0.3–0.8%, and hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer at 0.5–1.5%.

PVA gives the strongest film but the least flexibility. It works for a “lifting” or “tightening” positioning where the brand wants a perceptible tensioning effect — some brands actually market this sensation. But at concentrations above 2.5%, we start seeing white cast on deeper skin tones, and that’s a non-starter for most global SKUs.

The acrylate crosspolymers give better flexibility but are pH-sensitive. Drop below pH 5.0 and the film network starts to collapse. That matters because a lot of the actives we’re combining in eye serums — ascorbic acid derivatives, certain peptides, niacinamide at high load — push the system toward lower pH. We now require a pH compatibility check before we finalize film former selection on any brief. Learned that the hard way on a project where the formula looked perfect at pH 6.2 in the lab and drifted to pH 4.8 by week 6 of stability.

For regulatory context on polymer ingredients, EU Cosmetics Regulation 1223/2009 Annex III restrictions apply to certain acrylate monomers — worth checking if you’re targeting EU markets, because residual monomer limits are enforced at the finished product level, not just the raw material spec.

Critical Selection Criterion 2: Hydrogel Patch Specification — Gel Strength, Adhesion, and Release Rate #

Hydrogel patches are a manufacturing commitment, not just a formula decision. We run patch production on a separate line from our liquid fills, and the lead time for a new patch format is typically 10–14 weeks from brief to first pilot batch. Brands that come to us expecting patch development to run on the same timeline as a serum are usually surprised.

The three parameters we specify upfront for every patch brief:

Gel strength (measured by texture analyzer, 10mm probe, 1mm/s): our working range is 200–800 g/cm². Below 200, the patch tears during peel-off. Above 800, it doesn’t conform to the orbital contour and consumers report discomfort. Most of our eye patches land at 350–500 g/cm².

Peel adhesion: we target 0.3–0.8 N/25mm on a standardized skin simulant. Too low and the patch migrates during the wear period. Too high and removal causes erythema — which is a serious problem for the eye area specifically.

Active release rate: this is where the clinical story lives. For a 20-minute express patch, we target 60–70% active release within the first 15 minutes. For an overnight patch, we want a flatter release curve — 40–50% at 4 hours, 80–90% at 8 hours. The polymer matrix composition (typically carbomer, xanthan gum, or polyacrylamide-based systems) controls this, and we tune it by adjusting crosslink density and hydrophilic/lipophilic balance of the gel.

One clinical reference we use internally: a split-face, double-blind study (n=42, 8 weeks, twice-weekly application) using a polyacrylamide-based hydrogel patch loaded with 3% caffeine and 5% niacinamide showed a 28% reduction in periorbital puffiness score and 19% improvement in fine line depth by profilometry at week 8. That’s a reasonable benchmark for what a well-formulated patch can deliver. What it doesn’t tell you is the stability story — that same formula had a 6-month shelf life at 25°C/60% RH but failed at 40°C/75% RH by week 10. Packaging solved it, but it added cost.

For patch substrate sourcing and testing, we follow ISO Standards for biocompatibility testing on medical-adjacent materials, even though cosmetic patches don’t require it. It’s a quality floor we set ourselves.

Critical Selection Criterion 3: Preservative System for the Eye Area #

Honestly, most brands underestimate this. The eye area is a high-risk zone for preservative selection — not because the formulas are harder to preserve, but because the tolerance for irritation is essentially zero. A preservative system that passes challenge testing and sits comfortably in a face serum can cause stinging, tearing, and conjunctival irritation when it migrates to the eye surface during application or sleep.

Our default approach for eye serums: phenoxyethanol at ≤0.5% (half the typical face serum load) combined with ethylhexylglycerin at 0.1–0.3%. This system passes ISO 11930 challenge testing at criterion A for most aqueous eye serum bases. For patch formats, we often shift to a hurdle approach — low water activity through humectant loading (glycerin at 15–25%), pH control at 4.5–5.5, and a minimal preservative top-up.

We’ve stopped recommending methylisothiazolinone (MI) for any eye area product. The sensitization data is clear enough, and the SCCS Scientific Opinion on MI has been unambiguous since 2014. Some brands still ask for it because it’s cheap. We push back every time.

The failure mode we see most often: worked fine at 500g lab scale. At 200kg production, gram-negative organisms appeared at week 8 of preservative challenge testing. The root cause was a change in water quality between the lab and production facility — conductivity went from 0.8 µS/cm to 4.2 µS/cm, which altered the ionic environment enough to reduce phenoxyethanol efficacy. We now require production-equivalent water for all scale-up batches. That’s a process control point, not a formula point, but it matters.

Critical Selection Criterion 4: Active Ingredient Compatibility in the Eye Zone #

The eye contour has a different active ingredient logic than the rest of the face. Retinol, for example — we formulate it routinely for face serums at 0.1–0.3%, but for eye area products we typically cap at 0.05% and always encapsulate. The skin is thinner, turnover is different, and the risk of barrier disruption is higher. See our detailed notes on retinoid technology for the full stability and encapsulation framework.

Peptides are the primary workhorse for eye serums in our portfolio. Acetyl hexapeptide-3 (Argireline) at 5–10%, palmitoyl tripeptide-1 and tetrapeptide-7 (Matrixyl 3000) at 3–5%, and eyeseryl (acetyl tetrapeptide-5) at 5% for puffiness. These are well-characterized, stable across pH 5.0–7.0, and compatible with most film former systems. The peptide-film former interaction is something we check specifically — some cationic peptides will complex with anionic film formers and drop out of solution. We’ve seen this with certain arginine-terminated sequences at concentrations above 8%.

Caffeine at 2–3% for microcirculation support is almost universal in our eye serum briefs. It’s cheap, stable, and the consumer perception data is strong. We’re less convinced the clinical evidence for caffeine’s effect on dark circles is as robust as the marketing decks suggest — the mechanism is plausible but the controlled trial data is thin. We tell brands that honestly.

For brands targeting the NMPA registration pathway for China, eye area products with certain actives (including some peptides and whitening agents) may require additional safety dossiers. Check the current NMPA Cosmetic Regulation requirements before finalizing your active selection — the restricted ingredient list has been updated multiple times since 2021.

For a deeper look at how we approach peptide selection and stability, see our peptide and growth factor formulation guide.

Where Most Brands Get the Packaging Wrong #

Packaging for eye serums is not an afterthought. It’s a formulation variable. We’ve had perfectly stable formulas fail in the wrong container.

The two failure modes we see repeatedly: oxygen ingress through non-barrier packaging degrading ascorbic acid derivatives within 8 weeks, and metal ion contamination from low-quality aluminum tubes catalyzing oxidation in peptide-rich formulas. For any eye serum with an antioxidant or peptide active, we specify either airless pump or nitrogen-purged glass dropper as the primary packaging options.

Airless pump adds $0.40–$0.80 per unit at MOQ 3,000–5,000 units. Most indie brands can absorb that. What they often can’t absorb is the minimum order quantity for custom airless components — typically 10,000 units minimum for a branded pump head. That’s a real commercial constraint and we raise it early.

For patches, the foil laminate pouch is non-negotiable. We specify a minimum 12-micron aluminum foil layer with EVOH barrier coating. Without it, moisture vapor transmission degrades the gel matrix within 3 months at ambient conditions. We rejected the first packaging vendor on one recent project because their foil spec was 9 microns — they said it was equivalent. It wasn’t. Stability data at 40°C/75% RH showed gel strength dropping 35% by week 6 in their packaging versus 8% in the spec-compliant pouch.

It’s not a perfect solution. Even with correct packaging, some hydrogel formulas show slow syneresis over 18 months. We haven’t fully solved this one. Our current approach — adding 0.5–1.0% xanthan gum as a secondary network stabilizer — works but it’s not elegant.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions we ask when an eye serum or patch brief lands on our desk.

If you’re targeting EU and US simultaneously, your preservative system, film former selection, and any whitening actives need to be cleared against both EU Cosmetics Regulation 1223/2009 and FDA Cosmetics Guidelines before we finalize the formula. That’s not a legal review — that’s a formulation constraint that affects ingredient selection from day one.

If you’re targeting China, the NMPA pathway for eye area products adds 6–9 months to your timeline for certain actives. Plan for that.

On format: if you want a patch, commit to it early. The substrate, gel matrix, and die-cut tooling are all custom. We can’t pivot from patch to serum at week 8 without restarting.

What to include in your brief:

1. Target market(s) and regulatory pathway (EU, US, China, or combination)
2. Format commitment: lightweight serum, film-forming serum, hydrogel patch, or combination kit
3. Key actives and any non-negotiable concentrations (with justification if above standard range)
4. Skin feel and finish descriptor: matte film, dewy, invisible, cooling sensation
5. Packaging format preference and MOQ ceiling — this affects formula viscosity and fill process
6. Shelf life target: 18 months or 24 months (affects preservative system and stability testing scope)
7. Claim ambitions: functional claims (e.g., “reduces puffiness in 20 minutes”) require supporting data — tell us upfront if you need a clinical study built into the project

Frequently Asked Questions #

Q: We want to put 10% Argireline on the pack — is that actually stable in an eye serum?

Acetyl hexapeptide-3 is stable at 10% in aqueous systems at pH 5.0–6.5, so the stability answer is yes. The question we’d ask back is whether your film former system is anionic — if it is, you may see complexation and turbidity above 8%. We’d run a quick compatibility screen before committing to that concentration. Most of our eye serum projects land at 5–8% for this reason.

Q: Can we do a serum and a patch in the same product launch, sharing the same formula base?

Short answer: not really. The patch gel matrix requires a fundamentally different rheology and polymer system than a pourable serum. You can share actives and fragrance, but the base is a separate development track. Budget for two formulas, two stability studies, and two sets of challenge testing. Timeline impact is roughly 4–6 additional weeks.

Q: How long does a hydrogel patch stay effective once the foil pouch is opened?

Once opened, the patch should be applied immediately. The gel begins losing moisture within 15–20 minutes of air exposure at typical ambient conditions (23°C, 40–50% RH), and active concentration at the skin interface drops as the gel dries. We specify single-use foil pouches for exactly this reason — resealable packaging doesn’t solve the problem.

Q: Our brand is clean beauty — what preservative options do we have for the eye area?

The honest answer is that your options are narrower than for a face serum. We can build a system around glycerin at 20%, pH 4.8–5.2, and low-level ethylhexylglycerin at 0.2%. It passes criterion B on ISO 11930 challenge testing for most of our bases. Criterion A is harder without phenoxyethanol. If your clean beauty positioning prohibits phenoxyethanol, we need to know that upfront — it changes the water activity strategy and may affect your active loading ceiling.

Q: What’s the minimum order quantity for a custom hydrogel patch?

For a custom die-cut shape with branded foil pouch, our MOQ is typically 20,000 units per SKU. Standard oval shape with stock pouch can go as low as 10,000 units. Below those numbers, the tooling cost per unit makes the project commercially unviable for most brands. We can discuss amortizing tooling cost over multiple orders if you’re planning a range.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.